- Precision Medicine & Ion Channel Retreat 2019
- Precision Medicine & Ion Channel Retreat 2018
- Precision Medicine & Ion Channel Retreat 2017
- Precision Medicine & Ion Channel Retreat 2016
- Ion Channel Retreat 2015
- International Ion Channel Retreat 2014
- Ion Channel Retreat 2014
- Ion Channel Retreat 2013
Vancouver, British Columbia, Canada
August 9th – 11th, 2017
Testimonials from the 2017 Meeting
Thank you for attending our 2017 Precision Medicine & Ion Channel Retreat!
For our 15th Annual Retreat, we decided to bring the meeting back to Vancouver, Canada. It was met with a warm welcome, of new faces of Precision Medicine, to reunions of ion channel colleagues.
On the Ion Channel side, we incorporated new disease targets, as speakers introduced creative ways, and new drug discovery techniques with the latest technology in the field. We had a parallel session as well, that included new topics of ion transporters, and CiPA related cardiac toxicity.
We added new topics to this year’s Precision Medicine section, including immunotherapy, liquid biopsies, clinical applications of NGS, and our interdisciplinary session on novel perspectives of ion channels in Precision Medicine. This was nicely summarized by our panel discussion, looking at ion channel associations with oncology, and sharing the perspective from Precision Medicine researchers.
If you have any questions, feel free to contact our organizer, email@example.com
Before you know it, we’ll be organizing the 2018 Retreat very soon! We welcome your feedback, and any questions you may have.
Aurora’s Ion Channel Retreat (ICR) began in 2003 and has since become one of the most recognized events for Ion Channel scientists to share ideas and connect with each other. Due to the success of the inaugural Precision Medicine & Ion Channel 2016 last year in Guangzhou, Aurora is proud to continue the joint topic retreat this year.
Aurora’s history and experience in hosting Ion Channel conferences can boost potential new research opportunities and innovations for Precision Medicine. The PM&ICR2017 will showcase Ion Transporter technology in Pathogenesis and Drug Discovery. Likewise, the Precision Medicine session will also be refocusing the topics towards Cancer Diagnosis and Treatment, Liquid Biopsy, Clinical Next Generation Sequencing (NGS) technology, Immunotherapy, and Biotechnology.
Precision Medicine Session
- Novel Perspective of Ion Channels in Precision Medicine
- Molecular Diagnostic Technologies
- Cancer Diagnosis and Treatment
- Liquid Biopsy in Oncology
- Liquid Biopsy for Clinical Practice
- Immunotherapy: emerging applications and challenges
- Applications of Next Generation Sequencing
- Microarray and Biotechnology
Ion Channel Session
- Ion Channel Structure and Function
- Ion Channels as Disease Targets
- Ion Channels as Pain Targets
- Drug Discovery & Drug Development
- Screening Technologies
- Cardiac Safety and the CiPA Initiative
- Ion Transporters in Pathogenesis
- Ion Transporters in Drug Discovery
- Craig January, MD, PhD – Professor at the School of Medicine and Public Health, at the University of Wisconsin
- William Catterall, PhD – Professor and Chair of University of Washington Department of Pharmacology
- Arthur Brown, PhD – CEO of MemChan; former founder & CEO of ChanTest
- Yuko Sekino, PhD – Director of Pharmacology National Institute of Health Sciences, Japan
- Edward Stevens, PhD – Head of Electrophysiology at Pfizer, Cambridge, UK
- Dennis Lo, MD, PhD – Associate Dean, Faculty of Medicine at CUHK, Foreign Associate US Academy of Sciences
- George Chandy, MD, PhD – Professor at NTU SG and UC Irvine
- Kurt Stoeckli – President & CSO at Glenmark Pharmaceuticals, Switzerland
- Hailin Zhang, MD, PhD – Vice President of Hebei Medical University
- Richard Olsen, PhD – Distinguished Professor of Neuroscience at the David Geffen School of Medicine at UCLA
- Yuklam Lo – Secretariat, and Honorary Chairman, Hong Kong Biotechlogy Organization
- An Hailong – Hebei University of Technology; Professor
- Dan Minor, PhD – Professor, Biochemistry and Biophysics, Cellular and Molecular Pharmacology, University of California
- Steve Goldstein, MD, PhD – Director at the Institute of Pediatric Sciences, University of Chicago
- John Dunlop, PhD – VP, Neuroscience Research at Amgen, Professor of Neuroscience, University of St Andrews
- Laszlo Urban, MD, PhD – Executive Director at Novartis
- Jean-Pierre Valentin, PhD – Senior Director, Head of Investigative Toxicology at UCB